Whereas small-rely MBL rarely progresses to CLL, superior-count MBL progresses to CLL demanding therapy in a level of 1% to two% annually. Higher-rely MBL is distinguished from Rai 0 CLL according to whether the B-cell rely is over or below 5 × 109/L. Even though individuals with both equally higher-depend MBL and CLL Rai stage 0 are at enhanced r